LABORATORY RESEARCH JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis Scientists report that the histone H3 lysine 4 demethylase JARID1D, a male-specific protein, represses gene expression programs associated with cell invasiveness and suppresses the invasion of prostate cancer cells in vitro and in vivo. [Cancer Res] Abstract Hypoacetylation, Hypomethylation, and Dephosphorylation of H2B Histones and Excessive Histone Deacetylase Activity in DU-145 Prostate Cancer Cells The histone H2B of the prostate cancer cell line DU-145 was found to have hypoacetylation, hypomethylation, and dephosphorylation as compared to the non-malignant prostatic cell line RC170N/h. [J Hematol Oncol] Full Article The Interaction between Androgen Receptor and PDGF-D in the Radiation Response of Prostate Carcinoma Using murine PTEN-null prostate epithelial cell line and human prostate carcinoma LNCaP models, nuclear and cytosolic androgen receptor (AR) levels were determined by immunoblot analysis and the transcriptional activity of nuclear AR was assessed by RT-PCR analysis of its target genes with or without irradiation. [Prostate] Abstract A Quinazoline-Based HDAC Inhibitor Affects Gene Expression Pathways Involved in Cholesterol Biosynthesis and Mevalonate in Prostate Cancer Cells The anti-inflammatory and anti-cancer effects of a quinazoline epigenetic-modulator compound were determined in prostate cancer cell lines using a non-hypothesis driven transcriptomics strategy utilizing the Affymetrix PrimeView® Human Gene Expression microarray. [Mol Biosyst] Abstract | Full Article The Canine Prostate Cancer Cell Line CHP-1 Shows Over-Expression of the Co-Chaperone Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein α To evaluate androgen-independent neoplastic cell growth, a new canine prostate cancer cell line (CHP-1) was established in this study. CHP-1 over-expressed the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α, which is over-expressed in human androgen-independent prostate cancer. [Vet Comp Oncol] Abstract 27-Hydroxycholesterol Stimulates Cell Proliferation and Resistance to Docetaxel-Induced Apoptosis in Prostate Epithelial Cells Researchers determined the effect of 27-hydroxycholesterol (27-OHC) in human prostate epithelial cells RWPE-1. They found that 27-OHC stimulates proliferation and increases androgen receptor transcriptional activity. [Med Oncol] Abstract CLINICAL RESEARCH A Randomized Phase II Clinical Trial of Personalized Peptide Vaccination with Metronomic Low-Dose Cyclophosphamide in Patients with Metastatic Castration-Resistant Prostate Cancer Researchers investigated the effect of metronomic cyclophosphamide in combination with personalized peptide vaccination (PPV) on regulatory T cells and myeloid-derived suppressor cells, and whether it could improve the antitumor effect of PPV. [Cancer Immunol Immunother] Abstract Changes in Plasma Biomarkers following Treatment with Cabozantinib in Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of an Extension Cohort of a Phase II Trial Investigators performed a post hoc analysis to find associations between select plasma biomarkers and treatment response in patients with metastatic castration resistant prostate cancer who received cabozantinib 100 mg daily as part of a Phase II non-randomized expansion cohort. [J Transl Med] Full Article A Phase II Multimodality Trial of Docetaxel/Prednisone with Sunitinib Followed by Salvage Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy Scientists explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy. This was a Phase II single-arm prospective open-label trial with historic controls. [Prostate Cancer Prostatic Dis] Abstract |